The Injectable Suspensions Market is expected to witness a staggering CAGR going forward. The gamut of care is being driven by the usage of sensors, digital technologies, and wearables, thereby allowing the healthcare personnel to delve deep into the patients’ live – be it pre-operative, post-operative, or the period in between. Consumer tech companies are into making caregivers visible outside of the clinical environment a reality.
These are mostly prepared because the drug is insoluble in the delivery vehicle. These are used across various therapy areas like oncology, diabetes, cardiovascular diseases, dermatology, etc. These can be administrated subcutaneously or intravenously.
To remain ‘ahead’ of your competitors, request for a sample@ https://www.persistencemarketresearch.com/samples/32973
Due to various advantages like patient preference and ease of administration, injectable Suspensions are preferred over other methods. The injectable suspensions market is majorly driven by the rising prevalence of chronic diseases, acquisition and mergers between the companies, benefits of injectable suspensions, and approvals from the government authorities.
For instance, in 2017, FDA approved AstraZeneca’s injectable suspensions, Bydureon BCise, for the treatment of type 2 diabetes. Moreover, an increase in the awareness about the injectable suspensions and R & D investment by the companies for improving the product pipeline is expected to increase demand for injectable suspensions during the forecast period.
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/32973
- Novo Nordisk A/S
- Lilly
- Biocon Limited
- Pfizer Inc.
- BeiGene
- EnteraBio Ltd
- AbbVie Inc.
- Pfizer Limited
- Teva Pharmaceuticals USA Inc.
- Bristol-Myers Squibb Company
- Cipla Inc.
- Baxter International Inc.
- AstraZeneca.
For instance, in January 2021, FDA approved CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), for the treatment of HIV-1 infection.
Another region that is expected to dominate the market is Europe followed by Asia. This is due to the prevalence of chronic diseases in these regions. According to the Eurostat database, more than 1 out of 3 individuals’ aged 16 years or above is suffering from long-lasting illness. Furthermore, an increase in life science research is expected to drive the market.
Key Segments
By Route of Administration
- Intramuscular
- Subcutaneous
- Intravenous
By Indication
- Oncology
- Autoimmune disorder
- Dermatologic disorders
- Endocrine disorders
- Others
By Volume
- Small Volume Parenteral (SVP): volume <100ml
- Large Volume Parenteral (LVP): volume ≥ 100ml
- Hyper alimentation solutions
- Cardiolpagic solutions
- Irrigating solutions
- Peritoneal dialysis solution
- Others
By Mode of Delivery
- Single-dose injection
- Multiple-dose injections
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com